| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website http://www.wjon.org |
Review
Volume 9, Number 1, February 2018, pages 1-4
Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
Table
| Case reports | Patient | Age/sex | Diagnosis | Other immnuno-therapy | Chemotherapy | Presentation | HBA1C | Number of doses | Antibody | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| GAD: glutamic acid decarboxylase. | ||||||||||
| Malik et al [6] | 1 | 55/M | Melanoma | Ipilimumab | Dacarbazine | DKA | 10.70% | 9 cycles | Negative | On insulin |
| Gaudy et al [7] | 2 | 44/F | Melanoma | Ipilimumab | Not stated | DKA | 6.85% | 2 cycles | Negative | On insulin |
| Hughes et al [8] | 3 | 64/F | Melanoma | None | None | DKA | 7.40% | Not known | Negative | Not known |
| Chae et al [9] | 4 | 76/M | NSCLC | None | Carboplatin and paclitaxel | DM | 5.80% | 2 cycles | Positive anti-GAD | On insulin |
| Hansen et al [10] | 5 | 58/M | Melanoma | Ipilimumab | None | DM | 9.70% | 17 cycles | Positive anti-GAD | On insulin |
| Juan et al [11] | 6 | 54/F | Melanoma | Ipilimumab | None | DKA | N/A | 3 cycles | Positive anti-GAD | On insulin |